Jinping Lai

Prof. Jinping Lai

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Hepatology
Verified
Journal Article
Closed access
FYFlora Yang
Flora Yang
Leena Hilakivi-ClarkeLeena Hilakivi-Clarke
Leena Hilakivi-Clarke
ASAurpita Shaha
Aurpita Shaha
YWYuanguo Wang
Yuanguo Wang
XWXianghu Wang
Xianghu Wang
NKNingling Kang
Ningling Kang
Cancer cells often encounter hypoxic and hypo-nutrient conditions, which force them to make adaptive changes to meet their high demands for energy and various biomaterials for biomass synthesis. As a result, enhanced catabolism (breakdown of macromolecules for energy production) and anabolism (macromolecule synthesis from bio-precursors) are induced in cancer. This phenomenon is called “metabolic reprogramming,” a cancer hallmark contributing to cancer development, metastasis, and drug resistance. HCC and cholangiocarcinoma (CCA) are 2 different liver cancers with high intertumoral heterogeneity in terms of etiologies, mutational landscapes, transcriptomes, and histological representations. In agreement, metabolism in HCC or CCA is remarkably heterogeneous, although changes in the glycolytic pathways and an increase in the generation of lactate (the Warburg effect) have been frequently detected in those tumors. For example, HCC tumors with activated β-catenin are addicted to fatty acid catabolism, whereas HCC tumors derived from fatty liver avoid using fatty acids. In this review, we describe common metabolic alterations in HCC and CCA as well as metabolic features unique for their subsets. We discuss metabolism of NAFLD as well, because NAFLD will likely become a leading etiology of liver cancer in the coming years due to the obesity epidemic in the Western world. Furthermore, we outline the clinical implication of liver cancer metabolism and highlight the computation and systems biology approaches, such as genome-wide metabolic models, as a valuable tool allowing us to identify therapeutic targets and develop personalized treatments for liver cancer patients. Export

1 January 2013 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
AVAdeline Vanderver
Adeline Vanderver
DTDavide Tonduti
Davide Tonduti
GBGenevieve Bernard
Genevieve Bernard
JLJinping Lai
Jinping Lai
CRChristopher Rossi
Christopher Rossi
RSRaphael Schiffmann
Raphael Schiffmann
The 4H syndrome (hypomyelination, hypodontia, hypogonadotro-pic hypogonadism) is a newly recognized leukodystrophy. The classical form is characteriz

6 December 2021 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JLJinping Lai
Jinping Lai
HWHanlin L. Wang
Hanlin L. Wang
XZXuchen Zhang
Xuchen Zhang
HWHuamin Wang
Huamin Wang
XLXiuli Liu
Xiuli Liu
Context.—: Nonalcoholic fatty liver disease (NAFLD) encompasses steatosis and steatohepatitis. The cause may be multifactorial, and diagnosis requires correlation with clinical information and laboratory results. Objective.—: To provide an overview of the status of histology diagnosis of steatosis, steatohepatitis, and associated conditions. Data Sources.—: A literature search was performed using the PubMed search engine. The terms ‘‘steatosis,'' ‘‘steatohepatitis,'' ‘‘nonalcoholic fatty liver disease (NAFLD),'' ‘‘nonalcoholic steatohepatitis (NASH),'' “alcoholic steatohepatitis (ASH),” ‘‘type 2 diabetes (T2DM),'' “cryptogenic cirrhosis,” “drug-induced liver injury (DILI),” “immune checkpoint inhibitor therapy,” and “COVID-19 and liver” were used. Conclusions.—: Nonalcoholic fatty liver disease has become the most common chronic liver disease in the United States. NASH is the progressive form of nonalcoholic fatty liver disease. The hallmarks of steatohepatitis are steatosis, ballooned hepatocytes, and lobular inflammation. NASH and alcoholic steatohepatitis share similar histologic features, but some subtle differences may help their distinction. NASH is commonly seen in patients with metabolic dysfunction but can also be caused by other etiologies. Examples are medications including newly developed immune checkpoint inhibitors and viral infections such as coronavirus disease 2019 (COVID-19). NASH is also a common cause of cryptogenic cirrhosis but can be reversed. The results from recent clinical trials for NASH treatment are promising in reducing the severity of steatosis, ballooning, and fibrosis.

8 June 2019 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
DZDongwei Zhang
Dongwei Zhang
XLXiaoyan Liao
Xiaoyan Liao
YTYaoyun Tang
Yaoyun Tang
RMReid G. Meyer
Reid G. Meyer
DDDaniel L. VAN Dyke
Daniel L. VAN Dyke
JLJinping Lai
Jinping Lai
Background: Warthin-like mucoepidermoid carcinoma is a newly recognized rare entity and could be misdiagnosed as a benign Warthin tumor. We report such a case of a 36-year-old male who presented with a left parotid gland mass. Case Report: Fine-needle aspiration showed features suggestive of Warthin tumor. Following parotidectomy, grossly there was a 1.6 cm well-circumscribed multilobular mass with focal areas of cystic change. Microscopically, at low magnification it had histological features resembling Warthin tumor, while lining with squamoid cells with scattered mucocytes demonstrating mild cytologic atypia was observed at high magnification. Immunohistochemically, the tumor cells were positive for p40, p63, cytokeratin 5/6, cytokeratin 7, and cancer antigen 125, but negative for discovered on GIST-1 (DOG1). Mucicarmine stain highlighted intracellular mucin within mucocytes. Rearrangement of mastermind like transcriptional coactivator 2 (MAML2) (11q21) gene was shown to be present in tumor cells by fluorescence in situ hybridization, supporting the diagnosis of a low-grade Warthin-like mucoepidermoid carcinoma. The patient was disease-free 12 months after surgery. Conclusion: Warthin-like mucoepidermoid carcinoma has not been widely recognized and can be misdiagnosed as Warthin tumor. Testing for MAML2 rearrangement provides essential support for diagnosis in difficult cases.

7 May 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FYFeng Yin
Feng Yin
ZWZi-Hao Wu
Zi-Hao Wu
JLJinping Lai
Jinping Lai
New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

1 July 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
JLJinping Lai
Jinping Lai
JKJesse L. Kresak
Jesse L. Kresak
DCDengfeng Cao
Dengfeng Cao
DZDongwei Zhang
Dongwei Zhang
SZSharon Zhang
Sharon Zhang
XFXuemo Fan
Xuemo Fan